“De-escalation” strategy using micafungin for the treatment of systemic Candida infections: budget impact in France and Germany

References

• de la TorrePReboliACMicafungin: an evidence-based review of its place in therapyCore Evid20149273924596542
   PubMedGoogle Scholar
• RichardsonMLass-FlorlCChanging epidemiology of systemic fungal infectionsClin Microbiol Infect200814Suppl 4524
   PubMed Web of Science ®Google Scholar
• PfallerMADiekemaDJEpidemiology of invasive candidiasis: a persistent public health problemClin Microbiol Rev200720113316317223626
   PubMed Web of Science ®Google Scholar
• KarabinisAHillCLeclercqBTancredeCBaumeDAndremontARisk factors for candidemia in cancer patients: a case-control studyJ Clin Microbiol19882634294323356785
   PubMed Web of Science ®Google Scholar
• ZilberbergMDKothariSShorrAFCost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulationCrit Care2009133R9419545361
   PubMed Web of Science ®Google Scholar
• ZilberbergMDKollefMHArnoldHInappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort studyBMC Infect Dis20101015020525301
   PubMed Web of Science ®Google Scholar
• PappasPGKauffmanCAAndesDClinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of AmericaClin Infect Dis200948550353519191635
   PubMed Web of Science ®Google Scholar
• MartinMVThe use of fluconazole and itraconazole in the treatment of Candida albicans infections: a reviewJ Antimicrob Chemother199944442943710588302
   PubMed Web of Science ®Google Scholar
• CharlierCHartELefortAFluconazole for the management of invasive candidiasis: where do we stand after 15 years?J Antimicrob Chemother200657338441016449304
   PubMed Web of Science ®Google Scholar
• SnydmanDRShifting patterns in the epidemiology of nosocomial Candida infectionsChest20031235 Suppl500S503S12740235
   PubMed Web of Science ®Google Scholar
• KabirMAAhmadZCandida infections and their preventionISRN Preventive Med20132013763628
   Google Scholar
• ArendrupMCDzajicEJensenRHEpidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programmeClin Microbiol Infect2013198E34335323607326
   PubMed Web of Science ®Google Scholar
• MikulskaMDel BonoVRattoSViscoliCOccurrence, presentation and treatment of candidemiaExpert Rev Clin Immunol20128875576523167687
   PubMed Web of Science ®Google Scholar
• ArendrupMCUpdate on antifungal resistance in Aspergillus and CandidaClin Microbiol Infect201420Suppl 6424824372701
   PubMed Web of Science ®Google Scholar
• BaddleyJWPatelMBhavnaniSMMoserSAAndesDRAssociation of fluconazole pharmacodynamics with mortality in patients with candidemiaAntimicrob Agents Chemother20085293022302818591269
   PubMed Web of Science ®Google Scholar
• EmriTMajorosLTothVPocsiIEchinocandins: production and applicationsAppl Microbiol Biotechnol20139783267328423463246
   PubMed Web of Science ®Google Scholar
• Fernandez-RuizMAguadoJMAlmiranteBInitial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysisClin Infect Dis201458101413142124642553
   PubMed Web of Science ®Google Scholar
• Kale-PradhanPBMorganGWilhelmSMJohnsonLBComparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis infections: a meta-analysisPharmacotherapy201030121207121321114387
   PubMed Web of Science ®Google Scholar
• MesserSADiekemaDJBoykenLTendolkarSHollisRJPfallerMAActivities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida sppJ Clin Microbiol200644232432616455878
   PubMed Web of Science ®Google Scholar
• UllmannAJAkovaMHerbrechtRESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)Clin Microbiol Infect201218Suppl 7536723137137
   PubMed Web of Science ®Google Scholar
• KollefMAppropriate empirical antibacterial therapy for nosocomial infections: getting it right the first timeDrugs200363202157216814498753
   PubMed Web of Science ®Google Scholar
• MastertonRGCasamayorMMusingarimiPDe-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infectionsJ Med Econ201316111344135624003830
   PubMedGoogle Scholar
• BassettiMMolinariMPMussapMViscoliCRighiECandidaemia in internal medicine departments: the burden of a rising problemClin MicrobiolInfect2013196E281E284
   Google Scholar
• European Commission. EurostatTotal population database. Data for 1 January 20142014 Available from: http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&language=en&pcode=tps00001&tableSelection=1&footnotes=yes&labeling=labels&plugin=1Accessed September 12, 2014
   Google Scholar
• PfallerMADiekemaDJSheehanDJInterpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testingClin Microbiol Rev200619243544716614256
   PubMed Web of Science ®Google Scholar
• Diflucan Summary of Product Characteristics2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diflucan_30/WC500121908.pdfAccessed September 10, 2014
   Google Scholar
• Mycamine Summary of Product Characteristics2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000734/WC500031075.pdfAccessed September 10, 2014
   Google Scholar
• ChalmersCMBalAMManagement of fungal infections in the intensive care unit: a survey of UK practiceBr J Anaesth2011106682783121504935
   PubMed Web of Science ®Google Scholar
• PappasPGRotsteinCMBettsRFMicafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasisClin Infect Dis200745788389317806055
   PubMed Web of Science ®Google Scholar
• KuseERChetchotisakdPda CunhaCAMicafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trialLancet200736995721519152717482982
   PubMed Web of Science ®Google Scholar
• HornDLOstrosky-ZeichnerLMorrisMIFactors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two arge, prospective, micafungin trialsEur J Clin MicrobiolInfect Dis2010292223229
   Web of Science ®Google Scholar
• SlavinMASorrellTCMarriottDCandidaemia in adult cancer patients: risks for fluconazole-resistant isolates and deathJ Antimicrob Chemother20106551042105120202987
   PubMed Web of Science ®Google Scholar
• KubiakDWBryarJMMcDonnellAMEvaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysisClin Ther201032463764820435233
   PubMed Web of Science ®Google Scholar
• AnaissieEJDarouicheROAbi-SaidDManagement of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literatureClin Infect Dis19962359649728922787
   PubMed Web of Science ®Google Scholar
• PhillipsPShafranSGarberGMulticenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study GroupEur J Clin Microbiol Infect Dis19971653373459228472
   PubMed Web of Science ®Google Scholar
• RexJHBennettJESugarAMA randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National InstituteN Engl J Med199433120132513307935701
   PubMed Web of Science ®Google Scholar
• SipsasNVLewisRETarrandJCandidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infectionCancer2009115204745475219634156
   PubMed Web of Science ®Google Scholar
• MarfoKGuoYPharmacoeconomic analysis of micafungin (Mycamine) 100 mg and 150 mg daily In the treatment of candidemiaPT2009344196199
   Google Scholar
• KujathPLerchKKochendorferPBoosCComparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycosesInfection19932163763828132367
   PubMed Web of Science ®Google Scholar
• Nolla-SalasJSitges-SerraALeon-GilCCandidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICUIntensive Care Med199723123309037636
   PubMed Web of Science ®Google Scholar
• DupontBFLortholaryOOstrosky-ZeichnerLStuckerFYeldandiVTreatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin BCrit Care2009135R15919804626
   PubMed Web of Science ®Google Scholar
• LeroyOGangneuxJPMontraversPEpidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006)Crit Care Med20093751612161819325476
   PubMed Web of Science ®Google Scholar
• SchmalreckAFWillingerBHaaseGSpecies and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre studyMycoses2012553e124e13722233267
   PubMed Web of Science ®Google Scholar
• BitarDLortholaryOLe StratYPopulation-based analysis of invasive fungal infections, France, 2001–2010Emerg Infect Dis20142071149115524960557
   PubMed Web of Science ®Google Scholar
• GareyKWRegeMPaiMPTime to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional studyClin Infect Dis2006431253116758414
   PubMed Web of Science ®Google Scholar
• SgangaGClinical aspects of invasive candidiasis in the surgical patientDrugs200969Suppl 12932
   Web of Science ®Google Scholar
• UllmannAJAkovaMHerbrechtRESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)Clin Microbiol Infect201218Suppl 7536723137137
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceGuide to the methods of technology appraisal 20132013 Available from: http://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdfAccessed November 24, 2014
   Google Scholar
• RuhnkeMAntifungal stewardship in invasive Candida infectionsClin Microbiol Infect201420Suppl 6111824661820
   PubMed Web of Science ®Google Scholar
• ProwleJREcheverriJELigaboEVAcquired bloodstream infection in the intensive care unit: incidence and attributable mortalityCrit Care2011152R10021418635
   PubMed Web of Science ®Google Scholar
• SidhuMKvan EngenAKKleintjensJSchoemanOPalazzoMCost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UKCurr Med Res Opin20092582049205919575628
   PubMed Web of Science ®Google Scholar